Important pharmacy news and late-breaking industry information updated daily.

Sinonasal products make up one of the most popular categories in the U.S. OTC drug market. But too many product choices can confuse patients trying to select the right medication for their ailments.

Following widespread criticism, CDC on Friday reversed COVID-19 testing guidance suggesting that individuals who had close contact with an infected individual "do not necessarily need a test." Now, the agency recommends to people who have been in close

CDC scientists neither produced nor supported last month's recommendation playing down the need for COVID-19 testing among individuals who have been exposed to the virus but are asymptomatic, according to sources familiar with the matter and internal documents obtained by the New York Times.

Interim findings from Eli Lilly's ongoing COVID-19 drug trial show great promise for the study intervention, a monoclonal antibody produced from the plasma of recovered patients. Among more than 450 newly diagnosed cases of infection, the test drug markedly lowered levels of the virus and curbed symptoms.

According to previously unpublished data provided by CDC, thousands of inpatients contracted COVID-19 between May and June while hospitalized for other reasons. One-half of all U.S. hospitals voluntarily reported data on institution-acquired infections over the 9-week period.

Backed by clinical trial data, Eli Lilly and Incyte Corp. will pursue emergency use authorization for their rheumatoid arthritis drug baricitinib (Olumiant) as a treatment for COVID-19. Previous research has demonstrated that certain steroids, owing to their anti-inflammatory properties, may benefit infected patients.

The opioid epidemic has prompted several legislative and regulatory efforts aimed at inappropriate opioid prescribing. But some experts wonder whether oncology patients are getting their needs met amid the sea change.

California might be the first state to develop its own line of generic drugs.

President Trump's sweeping new executive order, which targets prescription drug pricing, is being met with skepticism and pushback.

Despite buzz about a COVID-19 vaccine possibly being available by the end of October, experts say the timetable will actually depend on how many volunteers become infected as Phase III trials progress. Once that number hits 150, study sponsors have a statistical foundation on which to compare outcomes among vaccine recipients vs.